VANCOUVER, Canada & DALLAS, TX, USA I July 02, 2025 I Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition” , or the “Company”), a biopharmaceutical ...

JERSEY CITY, NJ, USA I July 02, 2025 I Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced that the Phase 2 ELENA ...

CHELMSFORD, MA, USA & NOVI, MI, USA & DÜSSELDORF, Germany & TOKYO, Japan I July 02, 2025 I Asahi Kasei Pharma has started trial drug ...

Two oral presentations to highlight the safety, immunogenicity, and future development of AV-1959R for primary and secondary prevention of Alzheimer's disease ...

Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties ...

BASEL, Switzerland I July 02, 2025 I BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of ...

MADRID, Spain I July 2, 2025 I mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, is pleased to announce that the ...

BRIDGEWATER, NJ, USA I July 02, 2025 I VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR ...

OSLO, Norway I June 30, 2025 I BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they ...

MONTPELLIER, France I July 01, 2025 I Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of ...

SAN DIEGO, CA, USA I June 30, 2025 I Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...